

Belgian National Contact Point for the H2020 MSCA program

FNRS - MSCA ITN/RISE Info Session
October 5, 2018



de Duve Institute
Human Molecular Genetics

Cliniques universitaires St-Luc
Centre for Vascular Anomalies

Cliniques universitaires St-Luc
Centre for Human Genetics

copyright © Clin.univ.St-Luc / H. Depasse

Miikka VIKKULA, MD, PhD
Professor of Human Genetics,
Institut de Duve, University of Louvain (UCL) &
Walloon Excellence in Lifesciences and Biotechnology (WELBIO)
Brussels, BELGIUM

Planning

- 1) Plan well ahead: if possible : 3-6 months!**
- 2) Select a cohesive group of beneficiaries**
- 3) Add company/societal partners**
- 4) Administrative issues to all ASAP: PIC # etc.**
- 5) Foresee regular Skype/Webex meetings**
- 6) Ask for input early enough from partners for various Tables**

7) Read carefully guidelines, and address all in your application.

8) Structure for the scientific part is unusual

9) Gantt charts etc for interactions

**10) Secondments of ESRs important
Plan them logically and well!**

TABLE OF CONTENTS (*max. 1 page*)

| | |
|---|----|
| 1. EXCELLENCE | 5 |
| 1.1 Quality, innovative aspects and credibility of the research programme | 5 |
| 1.1.1 Introduction, objectives and overview of the research programme | 6 |
| 1.1.2 Research methodology and approach | 9 |
| 1.1.3 Originality and innovative aspects of the research programme | 10 |
| 1.2 Quality and innovative aspects of the training programme | 11 |
| 1.2.1 Overview and content structure of the training | 12 |
| 1.2.2 Role of non-academic sector in the training programme | 15 |
| 1.3 Quality of the supervision | 16 |
| 1.3.1 Qualifications and supervision experience of supervisors | 16 |
| 1.4 Quality of the proposed interaction between the participating organisations | 16 |
| 1.4.1 Contribution of all participants to the research and training programme | 16 |
| 1.4.2 Synergies between participants | 17 |
| 1.4.3 Exposure of recruited researchers to different (research) environments, and the complementarity thereof | 17 |
| 2. IMPACT | 17 |
| 2.1 Enhancing the career perspectives and employability of researchers and contribution to their skills development | 18 |
| 2.2 Contribution to structuring doctoral research training at the European level and to strengthening European innovation capacity | 19 |
| 2.2.1 Contribution of the non-academic sector to the doctoral training | 19 |
| 2.3 Quality of the proposed measures to exploit and disseminate the results | 19 |
| 2.3.1 Dissemination of research results | 19 |
| 2.3.2 Exploitation of results and intellectual property | 20 |
| 2.4 Quality of the proposed measures to communicate the activities to different target audiences | 21 |
| 2.4.1 Communication and public engagement strategy | 21 |
| 3. QUALITY AND EFFICIENCY OF THE IMPLEMENTATION | 21 |
| 3.1 Coherence and effectiveness of the work plan | 21 |
| Table 3.1 a Description of Work Packages | 21 |
| Table 3.1 b Deliverables List | 24 |
| Table 3.1 c - Milestones List | 25 |
| Table 3.1 d Individual Research Projects | 26 |
| 3.2 Appropriateness of the management structures and procedures | 30 |
| 3.2.1 Network organization and management structure | 30 |
| 3.2.2 Supervisory Board (SB) and other network bodies | 31 |
| 3.2.3 Recruitment strategy | 32 |
| 3.2.4 Progress monitoring and evaluation of individual projects | 32 |
| 3.2.5 Intellectual Property Rights (IPR) and exploitation management | 32 |
| 3.2.6 Gender aspects | 32 |
| 3.2.7 Data Management and Open Access | 33 |
| Table 3.2a Implementation Risks | 33 |
| 3.3 Appropriateness of the infrastructure of the participating organisations | 33 |
| 3.4 Competences, experience and complementarity of the participating | 34 |

- Why should Europe train young scientists to your area of interest?
- Research should not be isolated (not too academic)
- Benefits to many people/ many Europeans
- Well defined area of interest where there is a need to form young scientist for academia, industry, society
 - * Not too narrow
 - * Too large might be difficult for coherence of science
 - * Detailed description of the learning experience of the students



RESEARCH & INNOVATION

Marie Skłodowska-Curie actions

V.A. Cure



(V.A. = Vascular Anomalies)

A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies

V.A. Cure : Academic beneficiaries



- most, but not all, knew each other already
 - choose well your beneficiaries
- had 2 very involved beneficiaries to help search partners and to write

V.A. Cure : Industry beneficiaries

John WISEMAN
ASTRAZENECA
Mölndal, Sweden



Prateek SINGH
FINNADVANCE
Oulu, Finland



FinnAdvance



V.A. Cure partners




“cutting-edge” technologies

- including next-generation sequencing (including single-cell RNA-Seq)
- CRISPR-Cas genome editing
- generation of animal models with inducible deletion and mosaic analyses
- generation of iPSCs
- microfluidics
- *in vivo* phage display to identify endothelial targets
- light sheet-, confocal-, and multiphoton live-imaging

Network and Training

| Key technique/expertise/resource | will be used/applied by ESR no | | | | | | | | | | | | | |
|--|--------------------------------|---|---|---|---|---|---|---|---|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Advanced microscopic imaging of cells and tissues (KI) | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
| Single cell sequencing (KI) | | | | | | √ | √ | | | | | | | |
| Analysis of perivascular ECM remodelling (UO) | | √ | √ | √ | √ | √ | √ | √ | | | | √ | | √ |
| In vivo phage display technique (AZ) | | √ | √ | √ | √ | √ | | | | | | | | |
| TGFb/BMP signalling expertise (INS) | | | | | √ | | √ | √ | | | | | √ | √ |
| VA patient samples biobank (DDUV) | √ | √ | | | √ | √ | | | √ | | √ | √ | | |
| Mouse complex vascular phenotyping (UU) | | √ | √ | √ | | | | | √ | | | | | |
| VA zebrafish models (UP) | √ | | √ | √ | | √ | | √ | | | | | √ | |
| EC metabolism (MPI) | | | √ | √ | | | | | | | √ | √ | | |
| Microfluidics Platform (FA) | √ | | | | | √ | √ | √ | | | | | √ | √ |
| iPSCs (AZ) | √ | | | | √ | √ | √ | √ | √ | √ | | | | |
| High sensitivity mutation detection in biopsy samples (OB) | | √ | √ | | | | | | | | | | | |
| Human EC/mesenchymal stem cell co-culture model (FIC) | √ | | | | √ | √ | | √ | | | | | | |

Scientific work packages (max 4?)



| ESR | Ac. Exp. 1 | Ac. Exp. 2 | Ac. Exp. 3 | Ind. Exp.1 | Ind. Exp. 2 |
|-----|------------|------------|------------|------------|-------------|
| 1 | DDUV (h) | UO | UP | FA | OB |
| 2 | DDUV (h) | UO | UP | FA | OB |
| 3 | UP | UU | KI | AZ (h) | |
| 4 | UU (h) | UO | | OB | |
| 5 | UO | UP | | AZ (h) | |
| 6 | KI (h) | INS | UU | AZ | FA |
| 7 | UU (h) | KI | DDUV | FA | |
| 8 | UO (h) | DDUV | FIC | FA | |
| 9 | UP (h) | MPI | DDUV | LLS | |
| 10 | UP (h) | MPI | DDUV | LLS | |
| 11 | MPI (h) | DDUV | UU | AZ | |
| 12 | INS (h) | UP | UU | AZ | |
| 13 | INS (h) | KI | DDUV | FA | |
| 14 | KI | INS | | FA (h) | |

V.A. Cure Training Programme



V.A. Cure website - screencast

European Researchers' Night

Rare Disease Day


Patients' day of VASCAPA

Press releases and social media announcements

Facebook & Twitter: short descriptions of key findings, images, bullet points (All ESRs responsible)

Professional help from communication and IT offices of Universities and the companies.

We used figures, tables and schemes whenever possible



We have 4 planned workshops (1-2 days each)

- * Training of ESRs in various scientific, industrial, and societal aspects**
- * Reporting on scientific results**
- * Visits: industry and other partners**

We do **not** have a hired management company !


- Writing on ourselves
- Management with existing infrastructures
(already help from DDUV)
- Foresee hiring a project manager

V.A. Cure Network:

complementary contributions of all partners to the network.

**8 universities,
7 companies,
a hospital and
a patient
organisation**

The V.A. Cure network



Connection to networks to show that the research is not isolated and will bring benefits to many people.

Take home messages

- 1) Plan well ahead: if possible : 3-6 months!**
- 2) Select a cohesive group of beneficiaries**
- 3) Add company/societal partners**
- 4) Administrative issues to all ASAP: PIC # etc.**
- 5) Foresee regular Skype/Webex meetings**
- 6) Ask for input early enough from partners for various Tables**

7) Read carefully guidelines, and address all in your application.

8) Structure for the scientific part is unusual

9) Gantt charts etc for interactions

**10) Secondments of ESRs important
Plan them logically and well!**